Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor

Abstract Few treatments have proven effective for patients with chronic spinal cord injury (SCI). This study aimed to evaluate the efficacy and safety of acidic fibroblast growth factor (aFGF) in human SCI. This was an open-label prospective clinical trial of aFGF with an extended follow-up to 48 mo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chin-Chu Ko, Tsung-Hsi Tu, Jau-Ching Wu, Wen-Cheng Huang, Yun-An Tsai, Shih-Fong Huang, Hsueh-Chen Huang, Henrich Cheng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2018
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f178265967004f39aa60c5e1b3e90f18
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f178265967004f39aa60c5e1b3e90f18
record_format	dspace
spelling	oai:doaj.org-article:f178265967004f39aa60c5e1b3e90f182021-12-02T15:09:03ZFunctional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor10.1038/s41598-018-31083-42045-2322https://doaj.org/article/f178265967004f39aa60c5e1b3e90f182018-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-018-31083-4https://doaj.org/toc/2045-2322Abstract Few treatments have proven effective for patients with chronic spinal cord injury (SCI). This study aimed to evaluate the efficacy and safety of acidic fibroblast growth factor (aFGF) in human SCI. This was an open-label prospective clinical trial of aFGF with an extended follow-up to 48 months. All patients were treated with aFGF 3 times, including once directly applied to the injured spinal cord during neurolysis surgery, and twice via lumbar punctures at 3- and 6-months post-operation. Every patient was evaluated with standardized measurements of neurological functions. The trial initially enrolled 60 patients (30 cervical and 30 thoracolumbar SCI), but only 46 (21 cervical- and 25 thoracolumbar-SCI) completed the follow-up. The ASIA impairment scales, motor, pin prick, light touch, and FIM motor subtotal scores were all improved in both groups, except that the ASIA scores of light touch only demonstrated tendency of increase in the cervical-SCI group. All patients had a decrease in dependence, and there were no major adverse events or other oncological problems throughout the follow-up. At 48 months, the study demonstrated that aFGF was safe, feasible, and could yield modest functional improvement in chronic SCI patients. Further randomized control investigations are warranted for validation of its optimal dosage.Chin-Chu KoTsung-Hsi TuJau-Ching WuWen-Cheng HuangYun-An TsaiShih-Fong HuangHsueh-Chen HuangHenrich ChengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 8, Iss 1, Pp 1-10 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chin-Chu Ko Tsung-Hsi Tu Jau-Ching Wu Wen-Cheng Huang Yun-An Tsai Shih-Fong Huang Hsueh-Chen Huang Henrich Cheng Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor
description	Abstract Few treatments have proven effective for patients with chronic spinal cord injury (SCI). This study aimed to evaluate the efficacy and safety of acidic fibroblast growth factor (aFGF) in human SCI. This was an open-label prospective clinical trial of aFGF with an extended follow-up to 48 months. All patients were treated with aFGF 3 times, including once directly applied to the injured spinal cord during neurolysis surgery, and twice via lumbar punctures at 3- and 6-months post-operation. Every patient was evaluated with standardized measurements of neurological functions. The trial initially enrolled 60 patients (30 cervical and 30 thoracolumbar SCI), but only 46 (21 cervical- and 25 thoracolumbar-SCI) completed the follow-up. The ASIA impairment scales, motor, pin prick, light touch, and FIM motor subtotal scores were all improved in both groups, except that the ASIA scores of light touch only demonstrated tendency of increase in the cervical-SCI group. All patients had a decrease in dependence, and there were no major adverse events or other oncological problems throughout the follow-up. At 48 months, the study demonstrated that aFGF was safe, feasible, and could yield modest functional improvement in chronic SCI patients. Further randomized control investigations are warranted for validation of its optimal dosage.
format	article
author	Chin-Chu Ko Tsung-Hsi Tu Jau-Ching Wu Wen-Cheng Huang Yun-An Tsai Shih-Fong Huang Hsueh-Chen Huang Henrich Cheng
author_facet	Chin-Chu Ko Tsung-Hsi Tu Jau-Ching Wu Wen-Cheng Huang Yun-An Tsai Shih-Fong Huang Hsueh-Chen Huang Henrich Cheng
author_sort	Chin-Chu Ko
title	Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor
title_short	Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor
title_full	Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor
title_fullStr	Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor
title_full_unstemmed	Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor
title_sort	functional improvement in chronic human spinal cord injury: four years after acidic fibroblast growth factor
publisher	Nature Portfolio
publishDate	2018
url	https://doaj.org/article/f178265967004f39aa60c5e1b3e90f18
work_keys_str_mv	AT chinchuko functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT tsunghsitu functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT jauchingwu functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT wenchenghuang functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT yunantsai functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT shihfonghuang functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT hsuehchenhuang functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor AT henrichcheng functionalimprovementinchronichumanspinalcordinjuryfouryearsafteracidicfibroblastgrowthfactor
_version_	1718387974388842496

Functional improvement in chronic human spinal cord injury: Four years after acidic fibroblast growth factor

Ejemplares similares